3231:TSENomura Real Estate Holdings, Inc. Analysis
Data as of 2026-03-11 - not real-time
Latest Price
Risk Level: Medium
Executive Summary
Wistron Corp. (3231.TW) is trading at TWD 133, comfortably above its 20‑day SMA (130.4) but still below the 50‑day SMA (138.3), indicating a neutral short‑term trend. The RSI sits at 50.3 and the MACD histogram is positive, suggesting a modest bullish momentum supported by increasing volume. Valuation metrics are compelling: a trailing P/E of 16.3 is well below the industry average of 37, and a forward P/E of 10.6 points to significant upside, reflected in the analyst median target of TWD 190 – roughly a 44% upside from current levels. The dividend yield of 2.95% and a payout ratio under 50% are attractive, yet the sustainability is questionable given negative operating cash flow (‑TWD 158 B) and free cash flow (‑TWD 204 B), coupled with a high debt‑to‑equity of 148.7 and total debt of TWD 337 B. The stock’s beta of 0.67 and a volatility of 34.9% over the past 30 days imply lower market sensitivity but higher price swings. The Fear & Greed Index at 77.8 (“Extreme Greed”) signals strong market appetite, but geopolitical exposure across the U.S., Europe, and China adds geographic risk. Overall, the stock appears undervalued on a price basis but carries notable financial and operational risks.
Market Outlook
Short Term
< 1 yearKey Factors
- Positive MACD histogram and increasing volume indicate near‑term bullish pressure
- Undervalued P/E relative to industry peers
- Attractive dividend yield despite cash‑flow concerns
Medium Term
1–3 yearsKey Factors
- Forward P/E of 10.6 suggests earnings acceleration
- Analyst median price target of TWD 190 implies ~44% upside
- Low beta reduces market‑wide volatility exposure
Long Term
> 3 yearsKey Factors
- High leverage (debt‑to‑equity 148.7) and negative cash flows pose solvency risk
- Geopolitical exposure across Taiwan, China, U.S., and Europe
- Sustainable dividend uncertain without cash‑flow improvement
Key Metrics & Analysis
Financial Health
Technical Analysis
Valuation
Risk Assessment
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.